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Abstract 
Background: Concurrent chemoradiotherapy (CCRT) significantly increases the survival rate of esophageal squa‑
mous cell carcinoma (ESCC) patients with malignant fistulae. Recent clinical evidence has shown the benefits of 
enteral nutrition for malnourished cancer patients. In this study, we aimed to validate that, with the support of enteral 
nutrition, ESCC patients who develop malignant fistulae might be able to complete CCRT and achieve long‑term 
survival.
Methods: We reviewed the medical records of 652 patients with ESCC who received definitive CCRT at Sun Yat‑sen 
University Cancer Center between January 2010 and December 2012. Treatment outcome and toxicity were ret‑
rospectively evaluated in 40 ESCC patients with malignant fistulae. All the 40 patients were treated with CCRT and 
evaluated by clinical nutritionists using nutrition risk screening (NRS) before, during, and after treatment. Twenty‑two 
patients received a nasogastric tube, and 18 underwent percutaneous endoscopic gastrostomy feeding. The median 
energy intake was 2166 kcal/day. Treatment response was evaluated at 3 months after the completion of CCRT.
Results: With a median follow‑up of 18 months (range, 3–39 months), patients’ 1‑year overall survival (OS) rate 
was 62.5%, and the estimated OS time was 25.5 months. Univariate analysis showed that the NRS score (P = 0.003), 
increase in NRS score (P = 0.024), fistula closure (P = 0.011), and response to treatment (P < 0.001) were signifi‑
cantly associated with OS. Multivariate analysis showed that tumor response (P = 0.044) and increase in NRS score 
(P = 0.044) were independent predictors of OS. Grade 3 vomiting was observed in 8 patients (20.0%), grade 3 neutro‑
penia was observed in 11 patients (27.5%), and grade 3 cough was observed in 13 patients (32.5%); 2 patients (5.0%) 
died of massive bleeding during treatment.
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Background
Esophageal cancer is among 10 most common causes 
of cancer-related death in China [1]. Malignant fistulae 
between the esophagus and respiratory tract (ER fistula) 
or between the esophagus and mediastinum (EM fistula) 
are serious complications for patients with esophageal 
carcinoma [2]. Bronchopneumonia, sepsis, and massive 
bleeding are the most common terminal events observed 
in patients with a malignant fistula. Many patients with 
malignant fistulae eventually die, with a short median 
survival ranging from 1 to 6 weeks [3, 4]. Historically, the 
presence of ER fistula or EM fistula has been considered 
a relative contraindication for radiotherapy and chemo-
therapy. However, a large retrospective analysis showed 
that, for esophageal squamous cell carcinoma (ESCC) 
patients with malignant fistulae, radiotherapy significantly 
extended overall survival (OS) compared with supportive 
care [4]. Although most concurrent chemoradiotherapy 
(CCRT) trials for ESCC patients have excluded primary 
tumors with fistulae [5, 6], some studies reported that, 
for patients with locally advanced esophageal carcinoma, 
significant improvement in local control and OS can be 
achieved with CCRT compared with radiotherapy alone 
[7–9]. Koike et  al. [10] reported that CCRT with pro-
tracted cisplatin and 5-fluorouracil (5-FU) infusion for 
patients with T4 esophageal carcinoma and malignant fis-
tulae could lead to a 2-year survival rate of 22%.
Malnutrition is a common comorbidity in esophageal 
carcinoma patients, affecting up to 80% of patients at 
the time of diagnosis; for esophageal carcinoma patients 
with malignant fistulae, nutritional status is even worse 
[11]. Although CCRT has become a standard treatment 
strategy for esophageal carcinoma, this regimen is asso-
ciated with several toxicities, such as bone marrow sup-
pression, esophagitis, mucositis, nausea, and vomiting 
[7–10]. Recent clinical evidence has shown the benefits 
of enteral nutrition in malnourished cancer patients: it 
can maintain quality of life and improve nutritional sta-
tus by ensuring adequate nutrient intake [12–14]. There-
fore, with the support of enteral nutrition, ESCC patients 
who develop malignant fistulae might be able to complete 
CCRT and achieve long-term survival.
Building on our previous work that made the promis-
ing effects of CCRT on esophageal carcinoma [15, 16], we 
treated patients who had advanced esophageal carcinoma 
and ER or EM fistulae with aggressive CCRT combined 
with enteral nutrition support. Here, we reviewed and 
analyzed the clinical results of this treatment strategy for 
esophageal carcinoma patients who developed malignant 
fistulae before or during treatment.
Patients and methods
Patient and clinical data
We reviewed the medical records of 652 patients with 
ESCC who received definitive CCRT at Sun Yat-sen Uni-
versity Cancer Center, in Guangzhou, Guangdong, China 
between January 2010 and December 2012. Among 652 
patients, 73 ESCC patients were identified to have fis-
tulae. The patients were diagnosed according to the 
American Joint Committee on Cancer tumor, node, and 
metastasis (TNM) classification (7th edition). All the 
patients who met the following inclusion criteria were 
included in this study: (1) confirmed thoracic ESCC by 
pathologic analysis; (2) no previous cancer treatments 
and no distant metastases; (3) Eastern Cooperative 
Oncology Group (ECOG) performance status ≤2; (4) 
a complete evaluation, including physical examination, 
computed tomography (CT) scanning of the chest and 
abdomen, an upper gastrointestinal barium meal exam, 
and endoscopic ultrasound of the esophagus; and (5) 
meglumine diatrizoate mucilage (MDC) leakage with/
without endoscopy for fistulae assessment.
Clinical data collected from each patient included 
ECOG performance status, a nutrition assessment, age, 
sex, primary esophageal tumor location, clinical stage 
and T category of primary tumor, radiation dose, CCRT 
regimen, and tumor response to CCRT.
Enteral nutrition support and assessment
Before, during, and after CCRT, all patients were evalu-
ated by clinical nutritionists using nutrition risk screening 
(NRS). Patients were evaluated in terms of undernutri-
tion and disease severity, according to whether they are 
absent, mild, moderate, or severe, making a total score 
of 0–6; patients with a total score of ≥3 were classified 
as nutritionally at-risk. Undernutrition was estimated 
using three variables used in most screening tools: body 
mass index (BMI), percent of recent weight loss, and 
Conclusions: CCRT combined with enteral nutrition support is effective for ESCC patients with malignant fistulae. 
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ESCC who undergo CCRT.
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change in food intake. Diseases like hip fracture, chronic 
diseases, and tumor were scored 1; major abdominal 
surgery, stroke, diabetes, and hematologic malignancy 
were scored 2; head injury and bone marrow transplan-
tation were scored 3 [17]. Increased NRS score indi-
cated improved nutritional status of patients than before. 
When diagnosed with a malignant fistula, patients were 
administered enteral nutrition support. The patients 
either received nasal feeding or underwent a percutane-
ous endoscopic gastrostomy (PEG), and therefore dietary 
intake could be adjusted and to achieve energy balance 
and minimize weight loss based on patient weight that 
was continuously monitored.
Intacted protein enteral nutrition powder formula 
(Danone; Paris, France) was used for nasal feeding (each 
500-mL bottle provides 20  g of protein and 500 kcal of 
energy). Oral and/or enteral energy-rich and protein-rich 
supplements were added when needed. At all measure-
ment points, the PEG stoma site was observed and care 
advice was given when needed. Nutritional supplements 
were administered until 4–8 weeks after fistula closure.
All laboratory test values, including hemoglobin level 
and serum albumin level, were determined in the clinical 
laboratories of Sun Yat-sen University Cancer Center.
Radiotherapy and concurrent chemotherapy
During radiotherapy, the techniques used for patient 
immobilization, simulation, and treatment planning 
were performed according to a standard protocol in the 
Department of Radiotherapy at Sun Yat-sen Univer-
sity Cancer Center for esophageal carcinoma patients 
receiving three-dimensional conventional radiotherapy 
(3D-CRT) [18]. With the patient in the supine position, 
a cradle for immobilization was made with a vacuum. 
Individual patients were scanned from the atlas (C1) 
to the second lumbar vertebra (L2) level to cover the 
entire neck, lung, esophagus, and celiac lymph node 
regions. CT scans were performed with 0.5-cm thick-
ness slices. Briefly, the gross tumor volume (GTV-
esophagus) consisted of lesions diagnosed by biopsy 
or subsequent CT scans; tumor regions described on 
endoscopy but not observed on CT were also included 
in the GTV-esophagus. The criteria for GTV of posi-
tive lymph nodes (GTV-ln) based on CT scans were as 
follows: short axis size ≥10  mm, a lymph node with an 
infiltrative margin, or central necrosis. Two clinical tar-
get volumes (CTVs) for the patients were defined: CTV1 
comprised GTV-ln and 2 cm proximal and distal to the 
GTV-esophagus; CTV2 comprised the supraclavicular 
and mediastinal lymph nodes, GTV-ln, and 4 cm proxi-
mal and distal to the GTV-esophagus. PTV1 was defined 
as a 5-mm margin added to CTV1; PTV2 was defined as 
a 5-mm margin added to CTV2 [17]. All patients had a 
3D-CRT treatment plan that was calculated by the Pin-
nacle treatment planning system, and they were treated 
with a 6-MV linear accelerator (MIMiC; Nomos Corp., 
Sewickly, PA, USA). The median dose was 60 Gy for GTV 
(range, 46–68  Gy), 55  Gy for PTV1 (range, 40–68  Gy), 
and 46 Gy for PTV2 (range, 40–54 Gy). Dose constraints 
for critical organs were as follows: the maximum spinal 
cord dose <46 Gy, mean lung dose <17 Gy, and the lung 
volumes irradiated above 20 Gy (V20) <30%.
Two regimens of chemotherapy were used in the 
study: (1) concurrent chemotherapy consisted of cispl-
atin (20 mg/m2 per day) and 5-FU (500 mg/m2 per day), 
every 3  weeks; (2) docetaxel-based regimens consisted 
of docetaxel (60  mg/m2 per day) and cisplatin (60  mg/
m2 per day), every 3 weeks; or concurrent chemotherapy 
comprising cisplatin (25  mg/m2 per day) and docetaxel 
(25 mg/m2 per day), weekly [15, 16].
Follow‑up and treatment response assessment
The beginning of the follow-up period was defined as 
the last date of CCRT treatment. During the follow-
up period, patients underwent a chest CT scan every 
3  months, an upper digestive tract endoscopy and an 
abdominal ultrasonography every 6  months for 2  years 
after CCRT, and a subsequent chest CT scan, an endos-
copy, and an abdominal ultrasonography every 6 months 
thereafter. Bone scans were performed when patients 
were suspected to have bone metastases. The rates and 
time to treatment response or distant metastasis, dura-
tion of OS and local relapse were recorded.
MDC leakage evaluation and/or endoscopy were per-
formed every 2–3 weeks from the diagnosis of malignant 
fistulae until 4 weeks after fistula closure.
Tumor response evaluations were performed 
1–3 months after CCRT according to response evaluation 
criteria in solid tumors (RECIST) definitions. For the pri-
mary tumors, the responses include complete response 
(CR), partial response (PR), progressive disease (PD), and 
stable disease (SD) [15, 19]. Multiple failures comprised 
both local and distant failures after CCRT. Acute toxicity 
was graded using the National Cancer Institute Common 
Toxicity Criteria (version 4.0).
Statistical analysis
The study endpoint was OS, which was calculated as the 
time from the last date of radiotherapy to the date of 
death from any cause or to the date of the last visit before 
September 30, 2013. Continuous variables, such as age, 
hemoglobin level, serum albumin level, and radiation 
dose, were normalized as the sample median and then 
analyzed as nominal categorical variables. Each variable 
was assessed first in univariate analysis, and variables that 
reached a P value of less than 0.05 were further evaluated 
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in multivariate analysis. Survival curves were plotted 
using the Kaplan–Meier method. We fitted the propor-
tional hazards model using Cox regression. After testing 
for variable interactions, a forward stepwise elimination 
procedure was used to determine the best-fitting model. 
In the multivariate analysis, P values less than 0.05 were 
considered statistically significant. All statistical analyses 
were performed using SPSS 19.0 software (IBM, Chicago, 
IL, USA).
Ethics statement
Our thoracic multi-disciplinary team discussed the treat-
ment of all patients. Written informed consent was not 
obtained; instead, all clinical records were anonymized 
and de-identified prior to analysis. The entire study was 




Forty ESCC patients (37 men and 3 women) were path-
ologically diagnosed with malignant fistulae and were 
finally included in this study. Patient characteristics 
are detailed in Table  1. Most primary lesions (26/40, 
65.0%) were located in the middle thoracic esophagus. 
Twenty-two patients had stages III and IV disease, and 18 
patients had stages I and II disease; 5 had T1-2 lesion, 21 
had T3 lesion, and 14 had T4 lesion. The NRS scores of 
22 patients were 3–4 (moderate to severe impaired nutri-
tional status) before treatment, and 16 patients experi-
enced an increase in NRS score with nutrition support 
during CCRT. All patients received concurrent chemo-
therapy; most (33/40, 82.5%) received a docetaxel-based 
regimen. The median radiation dose was 60  Gy (range, 
46–68  Gy); 12 patients (30.0%) received a lower dose 
(46–58  Gy). Fistula closure was observed in 32 patients 
(80.0%). Twelve patients (30.0%) had a CR, and 20 (50.0%) 
had a PR.
Treatment outcomes
With a median follow-up of 18  months (range, 
3–39  months), the 1-year OS rate of all patients was 
62.5%, and the estimated OS was 25.5 months. Univariate 
analysis showed that, after CCRT completion, NRS score 
(P = 0.003), increase in NRS score (P = 0.024), fistula clo-
sure (P = 0.011), and response to treatment (P < 0.001) 
were significantly associated with OS (Table  2). Clini-
cal factors that were statistically significant (P < 0.05) in 
univariate analysis were further analyzed in a multivari-
ate analysis with the stepwise regression of variables. 
Only patients who had a tumor response (HR  =  3.49, 
95% CI 1.48–8.23, P  =  0.004) and increase in NRS 
score (HR  =  0.23, 95% CI 0.06–0.94, P  =  0.004) after 
CCRT were selected by the stepwise addition of factors 
in the final models. The 1-year OS rates of patients who 
achieved CR, PR, SD, and PD were 91.7%, 65.0%, 33.3% 
and 0%, respectively. The 1-year OS rates of patients with 
an increased and non-increased NRS scores were 74.1% 
and 38.5%, respectively (Fig.  1a–c). Patients with T4 
tumor and fistulae had an 1-year OS rate similar to that 
of patients with non-T4 tumor and fistulae who received 
nutrition supported during CCRT (57.1% vs. 69.6%, 
P = 0.198).
Calorie intake and nutritional status
Eighteen patients had malignant fistula before CCRT; 22 
patients developed fistula during treatment. In these 22 
patients, the median time from the beginning of CCRT 
to the formation of fistula was 22 days (range, 7–36 days). 
Patients were given enteral nutrition support when diag-
nosed with malignant fistula. Nasal feeding was admin-
istered to 22 patients; 18 underwent PEG feeding. The 
median energy intake was 2166 kcal/day; the median 
protein intake was 1.53 g/kg weight per day (range, 1.41–
1.76  g/kg weight per day). Twenty-two patients had an 
NRS score of 3–4 before CCRT; 6 had an NRS score of 
3–4 after treatment. The median time from diagnosis to 
fistula closure for all 40 patients was 5 weeks.
Toxicities
The most frequent toxicities observed were vomiting, 
neutropenia, esophagitis, and cough, with a large major-
ity of toxicity degrees being grade 1 or 2. Grade 3 vomit-
ing, neutropenia, and cough were observed in 8 (20.0%), 
11 (27.5%), and 13 patients (32.5%), respectively. Two 
patients (5.0%) died of massive bleeding during treat-
ment. Two patients (5.0%) developed re-perforation after 
the initial fistula closure.
Discussion
Our study demonstrated that CCRT combined with 
enteral nutrition support offers a cure for malignant fis-
tulae. In our study, 40 patients who underwent CCRT 
for esophageal carcinoma with a malignant fistula had an 
estimated OS of 25.2 months, with 62.5% of the patients 
remaining alive at 1 year after treatment.
CCRT has been used as a primary therapeutic regi-
men for more and more patients who have unresectable 
esophageal carcinoma, who decline surgery, or who are 
deemed medically unfit for surgery. Radiation Therapy 
Oncology Group 85–01 was the first trial to analyze the 
efficacy of radiochemotherapy as a definitive treatment, 
and it demonstrated the superiority of CCRT over radi-
otherapy alone with regard to 5-year OS rate [20]. His-
torically, the presence of a malignant esophageal fistula 
was considered a relative contraindication to CCRT. 
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Table 1 Characteristics of 40 esophageal squamous cell carcinoma patients with malignant fistulae
ECOG, Eastern Cooperative Oncology Group; NRS, nutrition risk screening; CCRT, concurrent chemoradiotherapy; DDP, cisplatin; 5-FU, 5-fluorouracil; CR, complete 
response; PR, partial response; SD, stable disease; PD, progressive disease
a These values are presented as median followed by range in parentheses. Other values are presented as the number of patients with the percentage in parentheses
b Based on the American Joint Committee on Cancer tumor, node, and metastasis (TNM) classification (7th edition)
c The patients with NRS score of 1–2 are not listed in this table
d Only the values that were compared between subgroups are listed and analyzed
e The data were not applicable
Characteristic No. of patients (%) 1‑year OS rated (%) P value
Sex 0.006
 Men 37 (92.5) 67.6
 Women 3 (7.5) 0.0
Agea (years) 58 (41–80)
ECOG performance status 0.267
 0–1 11 (27.5) 68.2
 2 29 (72.5) 55.2
Primary tumor location 0.403
 Upper 12 (30.0) 50.0
 Middle 26 (65.0) 65.4
 Lower 2 (5.0) 100.0
T category of primary tumorb 0.392
 T1 2 (5.0) 100.0
 T2 3 (7.5) 100.0
 T3 21 (52.5) 57.1
 T4 14 (35.0) 57.1
Clinical stage of primary tumorb 0.526
 IIA–IIB 2 (5.0) 100
 IIIA–IIIC 29 (72.5) 62.1
 IV 9 (22.5) 55.5
NRS score of 3–4c
 Before nutrition support 22 (55.0) –e
 After nutrition support 6 (15.0) –
Hemoglobin level after CCRTa (g/L) 110 (56–156) –
Total energy intakea (kcal/day) 2166 (1956–2213) –
Total protein intakea (g/kg per day) 1.53 (1.41–1.76) –
Fistula closure 32 (80.0) –
Time to fistula closurea (weeks) 5 (2–11) –
Fistula site 0.435
 Trachea and bronchus 7 (17.5) 57.1
 Mediastinum 33 (82.5) 63.6
Radiation dosea (Gy) 60 (46–68) <0.001
 <60 14 (35.0) 50.0
 ≥60 26 (65.0) 69.2
Concurrent chemotherapy 0.333
 DDP + 5‑FU 7 (17.5) 42.9
 Docetaxel‑based regimens 33 (82.5) 66.7
Clinical tumor response after CCRT <0.001
 CR 12 (30.0) 91.7
 PR 20 (50.0) 65.0
 SD 3 (7.5) 33.3
 PD 5 (12.5) 0
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Ahmed et al. [9] found that malignant ER fistulae could 
completely be cured in 4 of 5 patients (80%) treated with 
5-FU (400–600  mg/m2) by protracting continuous infu-
sion and 60-Gy radiotherapy. Muto et  al. [8] reported 
promising CCRT results for patients with malignant 
esophageal fistulae. Indeed, fistula was closed after CCRT 
in 17 of 24 patients (71%), with a median OS of 198 days 
as calculated from the fistula diagnosis. These results 
suggested that the presence of a malignant fistula was not 
a contraindication for CCRT, which was the treatment 
that provided the best chance for survival and palliation 
of dysphagia.
Most patients were selected for non-surgical therapy 
because of comorbidity or locally advanced disease. 
Esophageal perforation may be inevitable when patients 
with T4 esophageal tumors are treated with confor-
mal radiotherapy. Ishida et  al. [5] reported that 6 of 45 
patients (13%) with a T4 tumor and/or M1 lymph nodes 
developed esophageal-bronchial fistulae during CCRT, 
and CCRT was consequently terminated. Most previous 
CCRT trials for patients with advanced esophageal carci-
noma excluded the patients with fistulae; however, in our 
study, we found that patients with T4 tumor and fistulae 
who received nutrition support during CCRT had simi-
lar OS to patients with non-T4 tumor and fistulae (1-year 
OS rate, 57.1% vs. 69.6%, P = 0.198).
Furthermore, recent studies showed that the patients 
who underwent preoperative CCRT followed by sur-
gery and achieved a complete pathologic response to 
preoperative CCRT had excellent prognosis [21–23]. 
Although clinical CR after CCRT may not be significantly 
associated with pathologic CR [24], maximizing the CR 
rate is likely to increase the proportion of patients with 
the most favorable outcome, potentially increasing the 
survival rate of the whole group. In accordance with 
the published data above, the patients in our study who 
achieved CR had a 1-year survival rate of 91.7%; in the 
group of 8 patients who did not achieve CR (SD, n = 3; 
PD, n  =  5), 7 (87.5%) died within 1  year. These results 
suggested that even in esophageal carcinoma patients 
with malignant fistula, achieving clinical CR is a very 
important prognostic factor of long-term survival. In 
addition, patients who received a higher radiation dose 
and more cycles of chemotherapy had a better chance of 
achieving CR as well as extended OS than patients with 
lower radiation dose.
For esophageal carcinoma patients, malnutrition might 
be another important cause of pneumonia and massive 
bleeding. For patients undergoing chemotherapy and/or 
radiotherapy, minor malnutrition (weight loss  <10%) is 
also significantly associated with poor prognosis. In a ret-
rospective review of 1555 patients with gastrointestinal 
malignancies who underwent chemotherapy, Andreyev 
et  al. [25] suggested that weight loss at presentation 
may be an independent prognostic predictor for devel-
oping more severe dose-limiting toxicities (P  <  0.001), 
decreased response rate (P  =  0.006), and shorter OS 
(P < 0.001) for patients with gastric and colorectal neo-
plasms. For 350 patients with advanced esophageal car-
cinoma who were treated in 6 consecutive prospective 
trials, weight loss of more than 5% was a poor prognos-
tic factor (9 vs. 12 months, P = 0.006) [26]. According to 
Table 2 Univariate analysis of prognostic factors of overall survival in 40 esophageal squamous cell carcinoma patients 
with malignant fistulae
HR, hazard ratio; CI, confidence interval. ECOG, Eastern Cooperative Oncology Group; NRS, nutrition risk screening; CCRT, concurrent chemoradiotherapy; CR, 
complete response
The italicized P values are statistically significant
Variable HR (95% CI) P value
ECOG performance status (0–1 vs. 2) 0.76 (0.26–1.87) 0.567
Primary tumor location (upper vs. middle vs. lower) 0.44 (0.19–1.00) 0.051
T category of primary tumor 1.95 (0.68–5.56) 0.213
(T4 vs. non‑T4)
Clinical stage of primary tumor (stage II vs. stage III vs. stage IV) 1.55 (0.68–3.57) 0.300
NRS score before CCRT (≥3 vs. <3) 1.13 (0.69–1.86) 0.631
NRS score after CCRT (≥3 vs. <3) 5.14 (1.72–15.31) 0.003
Increased NRS score after CCRT (yes vs. no) 0.32 (0.12–0.86) 0.024
Hemoglobin level after CCRT (>110 vs. ≤110 g/L) 1.56 (0.72–3.24) 0.724
Fistula closure (yes vs. no) 3.78 (1.36–10.61) 0.011
Fistula site (tracheobronchus vs. mediastinum) 1.55 (0.50–4.82) 0.447
Radiation dose (≥60 vs. <60 Gy) 0.46 (0.17–1.23) 0.096
Tumor response after CCRT (CR vs. non‑CR) 3.53 (2.01–6.18) <0.001
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European Society for Clinical Nutrition and Metabolism 
guidelines on enteral nutrition for patients who receive 
external-beam radiotherapy or CCRT, every effort should 
be made to increase dietary intake and prevent ther-
apy-associated weight loss and radiotherapy interrup-
tion [27]. In our study, for most patients, we observed 
a gain in total mass, involving mainly lean mass, and an 
increase in weight. Our results also showed that enteral 
nutrition support increased the NRS score of malnour-
ished patients who received CCRT, and patients who 
had an increased NRS score had higher 1-year OS rate 
than those who did not have an increased score (74.1% 
vs. 38.5%, P = 0.016). It is generally thought that radio-
therapy interrupts normal wound-healing mechanisms 
by leading to changes in the vasculature, by affecting 
fibroblasts, and by varying the levels of regulatory growth 
factors [28, 29]. Studies of preoperative radiotherapy 
have shown an increased risk for wound-healing compli-
cations compared with postoperative radiotherapy [30]. 
For this reason, malignant esophageal fistulae were pre-
viously regarded as incurable. However, most patients 
died within 12  months if radiotherapy was terminated 
[9, 10]. In the present study, the median fistula diameter 
upon MDC was 4.3 mm, and adequate enteral nutrition 
support appeared to be sufficient for minor wounds. The 
median time from diagnosis of fistula to fistula closure 
was 5 weeks. Two patients developed re-perforation after 
fistula closure, due to low protein intake after they were 
released from the hospital. In contrast, 1 patient main-
tained a good nutrition status (NRS score = 1) even with-
out fistula closure. These results suggest that maintaining 
good nutritional status is important for fistula closure.
Compared with the results in other published studies 
[8–10], the higher treatment response and local control 
rates in our study might be due to the following: (1) the 
use of the 3D-CRT technique (3D-CRT has a better GTV 
high-dose coverage compared with two-dimensional con-
ventional radiotherapy, which was used in most previous 
studies); (2) the higher radiation dose was administered 
(in the present study, the median dose was 60 Gy, ranging 
from 46 to 68 Gy; better local control could be achieved 
with radiation dose greater than 60 Gy in ESCC); (3) all 
patients received concurrent chemotherapy; and (4) all 
patients received enteral nutrition support.
This retrospective study has several limitations, such 
as selection bias, different chemotherapy regimens, small 
sample size, and short follow-up. However, our results 
showed that, for ESCC patients, a malignant fistula is 
not a contraindication for CCRT. When enteral nutrition 
support is provided together with CCRT, patients can 
achieve promising improvement and have an increased 
potential to be cured.
Conclusions
CCRT combined with enteral nutrition support is an 
effective treatment regimen for ESCC patients with 
malignant fistulae, and these patients have an increased 
potential to be cured, especially those who achieve CR 
and an increase in NRS score. Careful observation and 
clinical nutrition support are required for patients with 
advanced T-category ESCC who underwent CCRT.
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